Event Details
近年来，从中央到地方政府陆续出台采购国产医疗器械及仪器的比例要求，促使外资医疗器械厂商开始重新评估在中国的供应链布局，如全球器械巨头西门子医疗，美敦力、飞利浦、GE等跨国企业都加快了在中国的本土化布局。
为精准聚焦外资医疗器械本地化生产中涉及到的全球和中国产业链重新布局、产品注册申报，本地化投资路径，财税政策等系列问题，本次政策分享会邀请了江苏省食药监局介绍进口医疗器械产品本土化注册申报流程和国产化认定政策，并通过近期知名外资医疗器械企业投资落户常州高新区的案例分享说明本土化投资路径和财税政策等问题。
随着美国政治格局的变化，多项税收改革提案获得了制度性支持，本次分享会将介绍主要的税收提案及其对生命健康产业的潜在影响。
活动语言为中文。
In recent years, the central and local governments have issued requirements on the proportion of purchasing domestically produced medical devices and instruments, making foreign medical device manufacturers start reevaluating their supply chain layout in China. Multinationals such as Siemens Healthcare, Medtronic, Philips, and GE healthcare have accelerated their localized layout in China.
To precisely focus on a series of issues involved in the localization production of foreign-funded medical devices, including the re-layout of global and Chinese industrial chains, product registration and declaration, localization investment pathways, and fiscal and tax policies, Jiangsu Provincial Food and Drug Administration official will introduce the localization registration and declaration process for imported medical device products and the localization certification policy. Additionally, through the recent case of foreign medical device company operating in Changzhou High-Tech Zone, audience will have insights into localization investment pathways and fiscal and tax policy issues.
Following recent political changes in the U.S., several tax reform proposals have gained institutional support, and this session will outline the key tax proposals and their potential impact on the life and health industry.
This is a Chinese session.
